Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10210456 | 0.91 | KMT2A (0.65) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL13647390 | 0.78 | EPHX2 (0.47) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL10612524 | 0.75 | KMT2A (0.61) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL15467216 | 0.75 | KMT2A (0.61) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL11057505 | 0.75 | LMNA (0.75) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL7440988 | 0.75 | KMT2A (0.61) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL10209768 | 0.75 | KMT2A (0.61) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL16037882 | 0.73 | — | — | |
| SCHEMBL18720725 | 0.73 | KMT2A (0.39) | KMT2ASMN1; SMN2LMNAHTTEPHX2 | |
| SCHEMBL14696521 | 0.72 | KMT2A (0.72) | KMT2ASMN1; SMN2LMNAHTTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | KMT2A 1548/4885SMN1; SMN2 271/4885LMNA 3755/4885 |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | KMT2A 2364/4885SMN1; SMN2 3769/4885LMNA 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.